Form 10-Q · Quarterly report
West Pharmaceutical Services 10-Q, filed Jul 23, 2026
- Filed
- CIK
- 0000105770
- Accession no.
- 0000105770-26-000099
Summary
For the quarter ended June 30, 2026, West Pharmaceutical Services reported GAAP diluted EPS of $2.15 and adjusted diluted EPS of $2.37, with six-month GAAP diluted EPS of $4.07 and adjusted diluted EPS of $4.50. The company renamed its Contract-Manufactured Products reportable segment to West Vantage and agreed to sell its SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie.
Key points
- Second-quarter 2026 GAAP operating profit was $179.1 million and adjusted operating profit was $197.4 million.
- Effective in the first quarter of 2026, West Pharmaceutical Services renamed its Contract-Manufactured Products reportable segment to West Vantage.
- West Pharmaceutical Services recorded $6.4 million of pre-tax M&A charges in the second quarter of 2026, including costs related to its agreement to sell the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie.
- After the U.S. Supreme Court in February 2026 ruled certain IEEPA tariffs unauthorized, West Pharmaceutical Services began applying for and receiving refunds for tariffs previously collected under IEEPA in the second quarter of 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION OVERVIEW The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2025 Annual Report. Our historical financial statements may not be indicative of our future performance. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.